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Objective: Nowadays, conventional analgesic agents, which are widely used for pain relief after cesarean
section, provide suboptimal analgesia with occasional serious side effects. We designed a randomized,
double-blind, placebo-controlled study to evaluate the analgesic efficacy of intrathecal ketamine added
to bupivacaine after cesarean section.
Methods: Sixty patients scheduled for cesarean section under spinal anesthesia were randomly allocated
to one of the two groups to receive either bupivacaine 10 mg combined with 0.1 mg/kg ketamine, or
bupivacaine 10 mg combined with 0.5 mL distilled water intrathecally. The time to the first analgesic
request, analgesic requirement in the first 24 hours after surgery, onset times of sensory and motor
blockades, the durations of sensory and motor blockades, and the incidences of adverse effects such as
hypotension, ephedrine requirement, bradycardia, and hypoxemia, were recorded.
Results: Patients who received ketamine had a significantly prolonged duration of anesthesia compared
with those who did not in the control group [95% confidence intervals (CI) 195e217; p ¼ 0.001].
The mean time to the first analgesic request was also significantly longer in ketamine group (95% CI
252.5e275; p < 0.001). The total analgesic consumption in the 24 hours following surgery significantly
lessened in the ketamine group compared with that of the control group (95% CI 2e2.5; p < 0.001). The
two groups did not differ significantly in intraoperative and postoperative side effects.
Conclusion: Intrathecal ketamine 0.1 mg/kg co-administered with spinal bupivacaine elongated the time
to the first analgesic request and lessened the total analgesic consumption in the first 24 postoperative
hours in comparison with bupivacaine alone in the control group following elective cesarean delivery.
Copyright  2014, Taiwan Society of Anesthesiologists. Published by Elsevier Taiwan LLC. All rights
reserved.
1. Introduction
Pain control after cesarean delivery is associated with improved
breastfeeding and infant rooming in. However, in parturient
women, we must balance the benefits of analgesia and known fetal
and maternal side effects induced, including bradycardia, respira-
tory depression, arterial hypotension, emetogenesis, and pruritus.1
Currently, opioids are widely used for pain relief, but they often
provide sub-optimal analgesia with occasional serious side effects.
Furthermore, it is reported that only a single administration of an
opioid may also induce a long lasting reduction of threshold of pain
sensitivity, leading to delayed hyperalgesia.2 Therefore, the search
for a new drug that may decrease the severity of postoperative pain
with minimal side effects seems mandatory. It is well known that
the activation of spinal N-methyl-D-aspartate (NMDA) receptors is
involved in the development of hyperalgesia.3 Adjusting regional
anesthesia with NMDA antagonists such as ketamine and magne-
sium so as to reduce the postoperative pain in patients undergoing
abdominal or orthopedic surgery is practicable.4,5 In a systemic
review of 24 studies, it was reported that ketamine has a significant
immediate and preventive analgesic benefit in 58% of the studies
(including both intravenous and neuraxial administration).6 Similar
efficacy of reduced opioid consumption was concluded from a
systemic review of 37 randomized trials of ketamine when given in
small doses in the preoperative period.7 In previous studies, it was
shown that the addition of ketamine to bupivacaine in spinal
anesthesia results in stable haemodynamics.8,9
Conflicts of interest: All authors declare no conflicts of interest.
* Corresponding author. Department of Anesthesiology, Faculty of Medicine,
Qazvin University of Medical Science, Shahid Bahonar Boulevard, P.O. Box
3419759811, Qazvin, Iran.
E-mail: mkhezri@qums.ac.ir, mkhezri88@gmail.com (M.B. Khezri).
Contents lists available at ScienceDirect
Acta Anaesthesiologica Taiwanica
journal homepage: www.e-aat .com
1875-4597/$ e see front matter Copyright  2014, Taiwan Society of Anesthesiologists. Published by Elsevier Taiwan LLC. All rights reserved.
http://dx.doi.org/10.1016/j.aat.2013.12.004
Acta Anaesthesiologica Taiwanica 51 (2013) 155e160
Author's personal copy
However, despite extensive discourses, there is still controversy
in the literature as to the safety and analgesic efficacy of ketamine
through the intrathecal route.10e15 Preservative-free racemic keta-
minewas shown to be devoid of neurotoxic effects after both single
and repeated administration in animals.10e12 Borgbjerg and
Svenssson12 administered preservative-free ketamine 5 mg intra-
thecally to rabbits for 14 consecutive days and concluded that it
bore no evidence of harmful neurotoxic effects, even after repeated
injections. It is suggested that various factors, like preservatives
(chlorobutanol and benzethonium chloride),the use of multiple
drugs for an extended period of time, and the indwelling intra-
thecal catheters may be responsible for neurological complica-
tions.10e14 By contrast, Yu et al15 reported that ketamine provided
potent protective effects against the ischemic reperfusion induced
spinal cord injuries. Furthermore, in obstetrics, ketamine has no
detrimental effect on uterine blood flow, and maternal or fetal
hemodynamics.16 Moreover, Horacek et al17 declared that a sub-
anesthetic dose of ketamine infusion induced changes similar to
those by monoamineric-based antidepressants, and that the
reduction in theta cordance could be a marker and a predictor of
the fast-acting antidepressant effect of ketamine. Therefore, these
beneficial effects may be valuable when ketamine is used as an
adjunct for spinal anesthesia in obstetric settings.
We hypothesized that ketamine might provide better pain relief
after cesarean section than conventional anesthetic agents. In
addition, unlike spinal opioids, ketamine does not produce pruri-
tus, respiratory depression, hemodynamic instability, or hyper-
algesia. In order to test our hypothesis, we designed this
randomized, double-blind, placebo-controlled study to evaluate
the postoperative analgesic effects of intrathecal ketamine added to
spinal bupivacaine in patients undergoing cesarean section.
2. Methods
The present study was a placebo-controlled, randomized,
double-blind clinical trial in which the patients, investigators, and
anesthesiologists were blinded to the designed treatment. Patients
were fully informed about the study protocol and submitted writ-
ten informed consent. The study was approved by the institutional
ethics committee and performed during July 2011 to February 2012.
Exclusion criteria included significant coexisting complications
such as hepatorenal and cardiovascular diseases, any contraindi-
cation to regional anesthesia such as local infection or bleeding
disorders, allergy to ketamine, long-term opioid use, or a history of
chronic pain. Using a computer-generated randomization schedule,
60 patients aged 18e45, American Society of Anesthesiologists
(ASA) physical status I or II, scheduled for cesarean section under
spinal anesthesia, were randomly allocated to one of the two
groups of 30 participants each. The Consolidated Standards of
Reporting Trials (CONSORT) recommendations for reporting ran-
domized, controlled clinical trials18 were followed (Fig. 1). Blinding
was achieved through the use of equal amounts of the study drugs
(2.5 mL) and the contain syringes used were labeled A and B ac-
cording to their content. Identically coded syringes prepared by the
operating room personnel who were not involved in the study,
were randomly handed to the anesthetist, who was unaware of the
Fig. 1. Consort flow diagram of the trial.
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identities of the drugs. The ketamine group (Group K) received
intrathecal bupivacaine 10 mg combined with 0.1 mg/kg ketamine
(Trittau, Germany), and the control group (Group C) received
intrathecal bupivacaine (Mylan S.A.S. Saint-Priest, France) 10 mg
combined with 0.5 mL distilled water. All patients were given an
intravenous preload of lactated Ringer’s solution at 5e7 mL/kg
prior to the subarachnoid block. With an aseptic technique, a 25-
gauge Quincke needle was inserted intrathecally via a midline
approach at the L4-5 interspace by the anesthetist, who was un-
aware of patient assignment, while the patient was in the sitting
position. Following a successful dural puncture, the anesthetic so-
lution was injected. The primary outcomes of this randomized,
double-blind, placebo-controlled clinical trial were to evaluate the
time to the first requirement of analgesic supplement and the total
analgesic consumption in the first 24 postoperative hours. In this
study, postoperative analgesia was defined as the time from the
intrathecal injection of anesthetic solution to the first requirement
of analgesic supplement. No additional analgesic was administered
unless requested by the patient. Patients were elucidated preop-
eratively for the use of the verbal rating scale (VRS) from zero to 10
(0 ¼ no pain, 10 ¼maximum imaginable pain) for pain assessment.
If the VRS exceeded four and the patient requested a supplement
analgesic, diclofenac Na Suppository 100 mg was given as post-
operative pain relief. If the time of administration from diclofenac
Na to patients’ request was less than 8 hours, intravenous pethidine
25 mg was given for breakthrough pain relief (VRS > 4). The sec-
ondary outcome of this study included the assessment of sensory
block onset time, maximum sensory level, onset of motor block,
duration of blockade, hemodynamic variables, the incidence of
hypotension, ephedrine requirements, bradycardia, hypoxemia
(saturation of peripheral oxygen < 90), pruritus, nausea, and
vomiting. Sensory block was assessed with a pinprick test. The
onset of sensory block was defined as the time from the end of
injection of the intrathecal anesthetic to the time at which pain at
the T10 dermatome was absent; the duration of sensory block was
defined as the time from the maximum block height to the T10
dermatome to regression of block, as evaluated by the pinprick test.
The maximal level of sensory block was evaluated by the pinprick
test after 20 minutes following the completion of injection. The
duration of spinal anesthesiawas defined as the time from injection
of spinal anesthetic to the first occasion when the patient com-
plained of pain in the postoperative period. Motor block was
assessed by the modified Bromage score (0 ¼ no motor loss;
1 ¼ inability to flex the hip; 2 ¼ inability to flex the knee; and
3¼ inability to flex the ankle); the onset of motor blockwas defined
as the time from intrathecal injection to Bromage block one,
whereas the duration of motor block was assumed when the
modified Bromage score was zero.
Mean arterial pressure (MAP) and heart rate (HR) were recorded
by an observer blinded to the patient group assignment, 5 minutes
prior to the intrathecal injection and 2 minutes, 4 minutes, 6 mi-
nutes, 8 minutes, 10 minutes, 15 minutes, and 20 minutes after the
injection. If the systolic blood pressure (SBP) fell to 20% below the
baseline (in the ward) or was < 90 mmHg, ephedrine 5 mg was
administered intravenously. Also, if HR was < 50 beats/minute,
atropine sulfate 0.5 mg was administered intravenously. A follow-
up telephone call was made 24 hours following the surgery and
again 1 month and 6 months later, during which the patients were
asked about the side effects, and dysesthesia of the lower limbs or
buttocks. The study data were collected and analyzed by a member
of the statistics department who was not involved in the study. To
calculate the sample size, data of previous similar studies were
taken into consideration.19e21 Sample size analysis determined that
a total of 25 patients (n ¼ 25) per group was required to detect a 20
minute difference in the median duration of analgesia between the
groups using the ManneWhitney U test, with a power of 0.9 and an
a equal to 0.05. We assigned 30 patients to each group to allow for
dropouts and protocol violations. Data were analyzed using SPSS
(version 15.0, SPSS Inc., Chicago, IL, USA). Parametric data were
expressed as mean and standard deviation (SD) and analyzed using
the independent t test. Continuous variables were tested for normal
distribution by the Kolmogorov-Smirnov test. Values normally
distributed were expressed as mean (SD) and those not normally
distributed were expressed as median (range). Nonparametric data
were expressed as median and interquartile range and analyzed
using the ManneWhitney U test. The effect of time on hemody-
namic parameters was analyzed using the repeated measurement
analysis of variance. The c2 test was used to analyze the incidence
of adverse events. Pain scores, motor scores, and sensory level were
evaluated within the study groups using the Wilcoxon’s signed
rank test. A p value < 0.05 was considered statistically significant.
3. Results
Among 63 patients initially enrolled in this study, three patients
were excluded because of logistic reason or violation of the study
protocol. Sixty patients were included and randomly assigned to
two groups for the study (Fig. 1).
There were no significant differences in age, height, and weight
between the two groups. The duration of surgerywas also similar in
the two groups (Table 1).
The mean onset time of sensory block was 91.00  20.98 sec-
onds in Group K and 78.5 26.0 seconds in Group C. The difference
between Groups K and C (95% CI ¼ 77.5e90; p ¼ 0.045) was sig-
nificant. Themean duration of sensory block timewas 143.7317.7
minutes in Group K and 133.53  32.68 minutes in Group C. The
difference between two groups (p ¼ 0.139) was shown to be
insignificant. The mean onset time of motor block was
88.66  31.67 seconds in Group K and 81.8  27.2 seconds in Group
C, with no statistically significant difference between the two
groups (p ¼ 0.374). The mean duration of motor blockade time in
Group K (170.43  22.70 minutes) was longer than that in Group C
(143.16  33.94 minutes), showing a statistically significant dif-
ference between the two groups (95% CI ¼ 147.5e165; p ¼ 0.001).
As shown in Table 2, the patients receiving ketamine had a signif-
icantly prolonged duration of anesthesia compared with those in
the control group (95% CI ¼ 195e217; p ¼ 0.001). Similarly, the
mean time to the first analgesic request was also significantly
longer in Group K (297.80  31.48 minutes) than in Group C
(236.34  22.20 minutes) and the difference was significant (95%
CI ¼ 252.5e275; p < 0.001). Likewise, the total analgesic con-
sumption in the 24 hours following surgery was significantly less in
Group K as compared with the control group (95% CI ¼ 2e2.5;
p < 0.001).
Despite aqueous volume loading prior to anesthetic block,
transient hypotension occurred at various time points in the two
groups. These patients were treated with 5 mg boluses of intra-
venous ephedrine to maintain the fall of SBP within 20% of the
baseline value or at 90 mmHg. The mean variation of MAP and
Table 1
Demographic data for the two study groups.
Group K (n ¼ 30) Group C (n ¼ 30) p
Age (y) 27.22  5.81 26.55  6.05 0.505
Weight (kg) 88.5  13.6 89.7  11.9 0.934
Height (cm) 161  8.4 161  6.1 0.743
Duration of surgery (min) 81.4  17.6 81.7  18.8 0.840
Values are presented as mean  standard deviation.
C ¼ control; K ¼ ketamine.
Evaluation of the analgesic effect of ketamine 157
Author's personal copy
HR was defined as the difference between the highest and the
lowest MAP and HR. The mean variation of MAP was
50.00  76.14 in Group C and 25.78  11.64 in Group K. The
difference between the two groups was insignificant (p ¼ 0.090).
The mean variation of HR was 32.86  10.17 in Group C and
33.90  11.62 in Group K, the difference of which was not sta-
tistically significant (p ¼ 0.715). Table 3 shows the repeated
measures analysis carried out to see the trend of change in HR
and MAP in the intraoperative period.
Although the mean of total ephedrine requirement in Group K
(1.83 3.82mg) was less than that of Group C (3.83 5.20mg), the
overall difference in ephedrine requirement between the two
groups was statistically insignificant (p < 0.088). As shown in
Table 4, the two groups did not differ significantly in intraoperative
and postoperative side effects including pruritus, nausea, vomiting,
headache, shivering, and respiratory depression.
No patient in either group had any sensory or motor compli-
cations identified within the 6 months following surgery. All
newborns in our study were free of any adverse effects.
4. Discussion
Based on the data found in the present study, it could be
concluded that in Group K the administration of intrathecal keta-
mine 0.1 mg/kg with spinal bupivacaine could cause a prolonged
intraoperative anesthesia and increase the time for the first request
for anesthetic after cesarean delivery, as compared with the control
group. Although these findings are consistent with those of some
previous studies,5,22e24 there are still conflicting data regarding the
effect of ketamine on postoperative analgesic consumption in other
studies.19,21 However, analgesic properties of ketamine are shown
to depend on antagonizing spinal NMDA receptors . It is well known
that the activation of spinal NMDA receptors induces hyperalgesia.
Moreover, it is reported that NMDA receptor antagonists have a
preventive effect on preoperative pain and may enhance the effi-
cacy of treatment of both acute and prolonged postsurgical pain.5
Furthermore, ketamine blocks the voltage-sensitive calcium chan-
nels, depresses sodium channels, and alters cholinergic neuro-
transmission, which is implicated in pain mechanisms; it also acts
as a noradrenergic and serotonergic uptake inhibitor, which is
involved in descending antinociceptive pathways.25 In a recent
study by Yang et al,26 it is reported that intrathecal ketamine
produces noticeable antinociception effects in rats and inhibits the
enhanced protein kinase C expression in the spinal dorsal horn in
response to formalin-induced pain.
The second observation which should be considered is that the
overall analgesic consumption in the first 24 hours in Group K was
less than that found in the control group. This finding is also
consistent with most previous studies.27e30 Results of the study by
Laulin et al27 indicated that sustained NMDA receptor blocking by
ketamine may improve postoperative morphine effectiveness. In a
systematic analysis of qualified clinical trials, Walker et al28 also
suggested that intrathecal racemic ketamine and Esketamine could
potentiate the antinociceptive effects of intrathecal morphine.29
Co-infused intrathecal ketamine attenuated morphine tolerance
to both somatic and visceral antinociception in animal models.30
The authors of the present study speculate that ketamine signifi-
cantly enhances the pethidine effects on postoperative pain man-
agement, thereby preventing the subsequent NMDA activation. The
NMDA receptor antagonist potentiates the opioid antinociception
by blocking the spinal C-fiber stimulation.27 Analgesic consumption
is known to be interrelated with primary hyperalgesia caused by
the augmentation of the sensitivity of primary afferent receptors,
rather than by central sensitization.27 Although the results of our
study are consistent with those of most previous studies,27e29,31on
Table 2
Characteristics of spinal anesthesia.
Group K (n ¼ 30) Group C (n ¼ 30) p
Onset time of
sensory block (s)
91.00  20.98 78.5  26.0 0.045
Duration of
sensory block (min)
143.73  17.7 133.53  32.68 0.139
Onset time of
motor block (s)
88.66  31.67 81.8  27.2 0.374
Duration of
motor block (min)
170.43  22.70 143.16  33.94 <0.001
Time to first request
of analgesia (min)
297.80  31.48 236.34  22.20 <0.001
Duration of spinal
anesthesia (min)
223.83  41.59 192.33  30.36 0.003
Total ephedrine
requirement (mg)
1.83  3.82 3.82  5.20 0.088
Total analgesic
consumption
in 24 h (number of
analgesia requests)
2(1e3) 3(2e3) <0.001
Data are presented as mean  standard deviation except for total analgesic con-
sumption in 24 hours, which is presented as median  interquartile range.
C ¼ control; K ¼ ketamine.
Table 3
Changes in hemodynamic variables.
HR MAP
Group K
n ¼ 30)
Group C
(n ¼ 30)
Group K
(n ¼ 30)
Group C
(n ¼ 30)
5 min
prior
to SA
100.90  13.16 98.73  13.61 94.93  3.41 95.05  5.36
2 min
after SA
97.06  15.15 101.73  16.15 79.34  15.97 74.76  15.95
4 min
after SA
92.23  12.36 97.26  15.03 80.97  3.07 74.93  13.71
6 min
after SA
92.26  12.44 98.90  17.58 85.74  9.60 82.12  12.61
8 min
after SA
87.56  14.40 92.73  17.36 91.41  6.83 87.54  10.57
10 min
after SA
88.36  17.71 91.70  13.68 91.27  5.15 89.11  7.93
15 min
after SA
92.40  16.87 89.13  14.32 90.83  5.77 92.66  9.09
20 min
after SA
94.13  18.49 88.26  14.49 89.73  5.56 82.96  5.27
25 min
after SA
93.83  15.75 90.86  12.33 86.14  4.52 86.38  4.66
30 min
after SA
93.16  14.83 89.50  11.36 107.70  76.69 86.97  6.53
p 0.803 0.59
Data are presented as mean  standard deviation.
C ¼ control; HR ¼ heart rate (bpm); K ¼ ketamine; MAP ¼ mean arterial blood
pressure (mmHg); SA ¼ spinal anesthesia.
Table 4
Side effects.
Group K (n ¼ 30) Group C (n ¼ 30)
Pruritus 1 (3.33) 0
Respiratory depression 0 0
Hypotension 7 (23.3) 8 (26.7)
Bradycardia 0 0
Nausea 1 (3.33) 3 (10)
Vomiting 0 1 (3.33)
Headache 0 0
Shivering 2 (6.7) 4 (13.3)
Data are presented as number of patients (%).
C ¼ control; K ¼ ketamine.
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the contrary, Kathirvel et al21 showed that 25 mg of intrathecal
esketamine (IT S ketamine) þ ketamine spared the local anesthetic
effect of bupivacaine, but failed to provide extended postoperative
analgesia or decrease the postoperative analgesic requirements.
The discrepancy of the results may be due to different methodol-
ogies and populations. For example, Kathirvel et al21 used a higher
dose (10 mg) of bupivacaine in the control group than that in the
ketamine group (7.5 mg). In this study, we used 10 mg bupivacaine
in both groups.
The third observation which should be noted is that the
administration of 0.1 mg/kg intrathecal ketamine with spinal
bupivacaine prolonged the onset of sensory block, whereas on the
contrary, the results by Unlugenc et al19 and Yanli and Eren31
suggested that the addition of intrathecal ketamine to spinal
bupivacaine shortened the onset of both sensory and motor
blockades. By contrast, Murali Krishna et al20 reported that the
onset of sensory or motor block was also similar in the two groups.
However, these apparently controversial results may be due to the
different populations, doses of ketamine, andmethodologies. In our
study, we used distilled water in the control group and ketamine
0.1 mg/kg in the ketamine group combined with spinal bupiva-
caine. The authors of the present study speculate that the pH of the
solution is a possible reason why ketamine prolongs the onset of
sensory block. The pH of ketamine hydrochloride is slightly acidic
(3.5e5.5), whereas the pH of distilled water (which we used in the
control group) is neutral (pH 7e7.4). Results of the clinical study by
Galindo32 suggested that the pH-adjusted solutions of local anes-
thetics produced a more rapid onset of blockade with better quality
and longer duration than the unmodified commercial preparations.
Moreover, Ritchie et al33 confirmed that the uncharged molecule is
essential for penetration to the intracellular receptor site. The
addition of ketamine decreases the pH of bupivacaine and there-
fore, the onset of the sensory block is prolonged.
The next observationwhich should be taken into account is that
the addition of intrathecal ketamine 0.1 mg/kg to spinal bupiva-
caine prolonged the duration of motor block with the sensory block
remaining untouched. This finding is in agreement with that found
in the study by Govindan et al,34 in which they claimed that the
motor blockade by intrathecal ketamine was longer than the sen-
sory blockade. By contrast, Togal et al9 described that the intra-
thecal Esketamine administered with a low dose of spinal
bupivacaine provided a shorter duration of action and less motor
blockade in elderly males. The results obtained by Togal et al9 may
be due to the utilization of a lower dose of bupivacaine in the ke-
tamine group. However, the discrepancy in the results of different
studies is probably due to the application of different methodolo-
gies and populations.
In our study, the mean of total ephedrine requirement in Group
K was less than that in Group C; nevertheless, the overall difference
in ephedrine requirement between the two groups was statistically
insignificant, yet the difference was obvious in the clinical settings.
The overall results of our study are consistent with studies by Bion,8
Murali Krishna et al20, and Kathirvel et al,21 who declared that the
use of intrathecal ketamine was associated with minimal hemo-
dynamic fluctuations. Bion8 reported that the transmission of ke-
tamine into the venous system (azygos vein) of the spinal cord
induced cardiovascular stimulation and hemodynamic stability
after spinal anaesthesia.8
The selection of a dose of intrathecal ketamine of 0.1 mg/kg was
based on the fact that several previous studies showed that the use
of such a dose could prolong the duration of analgesia without
additional side effects.9,20 By contrast, the endogenous opioid
analgesic system is enhanced by pregnancy during labor and the
early postpartum period, leading to reduced analgesic require-
ment.35 In our study, because the patients were pregnant, we used
a low dose of ketamine (0.1 mg/kg) in combination with spinal
bupivacaine 10 mg.
In the present study, we did not find any incidence of behavioral,
psychomimetic, or neurological complications in the patients
receiving ketamine intrathecally. This result is in harmony with the
findings by Bion,8 who reported that intrathecal ketamine acts
locally on the spinal cord nociceptors and does not act systemically
after being absorbed into the bloodstream. The second possible
cause of this finding is that we used a lower dose (0.1 mg/kg) of
ketamine compared with those of previous studies.36 Hawksworth
and Serpell36 observed psychomimetic manifestations in 50% and
30% of their patients while using intrathecal ketamine at doses of
0.75e0.9 mg/kg, respectively. Conversely, Togal et al9 used a low
dose ketamine (0.1 mg/kg) and observed no side effects.9 However,
it seems that the incidence of complications with intrathecal ke-
tamine is a dose-dependent phenomenon and thus the routine use
of such drugs in clinical practice should be postponed until its
safety is proved by further studies.
In conclusion, based on the data found in our study, it could be
concluded that intrathecal ketamine 0.1 mg/kg with spinal bupi-
vacaine caused a prolonged intraoperative anesthesia, increased
the time to the first analgesic request, and decreased the total
analgesic consumption in the first 24 postoperative hours as
compared with the control group following elective cesarean
delivery.
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